(262 days)
Not Found
No
The description details a rapid chromatographic immunoassay, which is a chemical test, and does not mention any computational or algorithmic components indicative of AI/ML.
No
The device is an immunoassay for detecting drugs in urine, providing a preliminary analytical test result. It is not designed to treat or alleviate a disease or condition.
Yes
Explanation: The device is described as a rapid chromatographic immunoassay for the qualitative and simultaneous detection of drugs in human urine, providing a "preliminary analytical test result" for diagnostic purposes related to drug screening.
No
The device description explicitly states it is a "chromatographic immunoassay" available in "test strip, dip panel, cassette panel and cup formats," which are all physical hardware components used for chemical analysis of urine.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states the device is for the "qualitative and simultaneous detection of one to nine of the following drugs... in human urine." This is a diagnostic test performed on a biological sample (urine) outside of the body (in vitro).
- Device Description: The description further clarifies it's a "chromatographic immunoassay for the rapid, qualitative detection of... in human urine." This confirms it's a laboratory-based test using an immunoassay method on a biological specimen.
- Performance Studies: The document details performance studies conducted on urine specimens, comparing the device's results to a confirmatory method (GC/MS). This is typical for the validation of an IVD.
- Predicate Device: The mention of a predicate device (Innovacon Spectrum II) with a K number (K061718) strongly indicates that this device is being submitted for regulatory clearance as an IVD, as predicate devices are used for demonstrating substantial equivalence in the IVD regulatory pathway.
All these points align with the definition and characteristics of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The LumiQuick's QuickProfile™ Single Drugs of Abuse and QuickProfile™ Multi-Drugs of Abuse Screen Devices are rapid chromatographic immunoassays for the qualitative and simultaneous detection of one to nine of the following drugs in a variety of combinations in human urine. Both devices are available in test strip, dip panel, cassette panel and cup formats. The designed cutoff concentrations and direct calibrator for these drugs are as follows:
AMP Amphetamine 1000 ng/ml
BAR Secobarbital 300 ng/ml
BZO Oxazepam 300 ng/ml
COC Benzoylecgonine 300 ng/ml
MTD Methadone 300 ng/ml
MAMP Methamphetamine 1000 ng/ml
OPI Morphine 300 ng/ml
PCP Phencyclidine 25 ng/ml
THC THC 11-nor-Δ"-THC-9-COOH 50 ng/ml
These devices are intended for prescription use only. These assays provide only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography / Mass Spectrometry (GC/MS) or Liguid Chromatography / Mass Spectrometry (LC/MS) are the preferred confirmatory method.
Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.
Product codes (comma separated list FDA assigned to the subject device)
LDJ, DIO, LCM, DJG, DKZ, JXM, DJC, DJR, DJS
Device Description
One-step, colloidal gold based chromatographic immunoassay for the rapid, qualitative detection of Amphetamine, Barbiturates, Benzodiazepines, Cocaine, Methadone, Methamphetamine. Opiates, Phencyclidine, and Marijuana in human urine.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Professional Use (non-POC)
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Minimum of 87 urine specimens were evaluated per drug, the study results demonstrate 100% accuracy between subject device and GC/MS confirmation level.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical tests were evaluated to establish the performance, functionality, safety and reliability of the OuickProfile™ devices. The performance evaluations include: Sensitivity, Precision - (usability), Stability (Device and Specimen), Reading Time, Specificity and Interference.
These studies evaluations were performed internally by professional personnel in LumiQuick Diagnostics, by qualified lab personnel, with proper calibrated / maintained lab equipments and under properly-controlled environmental conditions according to study requirements. All of the evaluated performances passed and meet the acceptance criteria set in the study protocol.
The Accuracy and Comparison Study was performed by comparing the GC/MS confirmed drug concentration on the QuickProfile™ devices and Predicate kit, using unaltered urine specimens, by lab professionals.
Minimum of 87 urine specimens were evaluated per drug, the study results demonstrate 100% accuracy between subject device and GC/MS confirmation level.
The product performance characteristics of LumiQuick's QuickProfile™ Single Drugs of Abuse and QuickProfile™ Multi-Drugs of Abuse Screen Devices were evaluated in the blind- labeled clinical specimen correlation study and in the blind-labeled spiked control studies including sensitivity, precision study, etc. Results of these studies demonstrate substantial equivalence between LumiQuick's QuickProfile™ Single Drugs of Abuse and QuickProfile™ Multi-Drugs of Abuse Screen Devices, GC/MS confirmation methodology, as well as Predicate device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
The Accuracy and Comparison Study was performed by comparing the GC/MS confirmed drug concentration on the QuickProfile™ devices and Predicate kit, using unaltered urine specimens, by lab professionals. Minimum of 87 urine specimens were evaluated per drug, the study results demonstrate 100% accuracy between subject device and GC/MS confirmation level.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.3870 Cannabinoid test system.
(a)
Identification. A cannabinoid test system is a device intended to measure any of the cannabinoids, hallucinogenic compounds endogenous to marihuana, in serum, plasma, saliva, and urine. Cannabinoid compounds includedelta -9-tetrahydrocannabinol, cannabidiol, cannabinol, and cannabichromene. Measurements obtained by this device are used in the diagnosis and treatment of cannabinoid use or abuse and in monitoring levels of cannabinoids during clinical investigational use.(b)
Classification. Class II (special controls). A cannabinoid test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
510(k) SUMMARY AS REQUIRED BY SECTION 807.92(C)
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA and 21 CFR 807.92(C)
The Assigned 510(k) number is: K130213
Date of Summary: October 8, 2013
OCT 1 8 2013
Common Name: Drugs of Abuse Screening Device
Regulatory Information:
- Regulation section: 21 CFR part 862.3870 (THC), 21 CFR part 862.3250 (COC), 21 CFR part 862.3650 (OPI), 21 CFR part 862.3100 (AMP), 21 CFR part 862.3170 (BZO), 21 CFR part 862.3610 (MAMP), 21 CFR part 862.3620 (MTD), 21 CFR part 862.3150 (BAR), non-applicable for PCP
-
- Classification: Class II, Unclassified (PCP)
-
- Product Codes: LDJ (THC), DIO (COC), LCM (PCP), DJG (OPI), DKZ (AMP), JXM (BZO), DJC (MAMP), DJR (MTD), DJS (BAR)
-
- Panel: Toxicology (91)
Applicant and Initial Importer:
LumiQuick Diagnostics, Inc. 2946 Scott Blvd. Santa Clara. CA 95054 Tel .: (408) 855-0061; Fax: (408) 855-0063
Contact Persons:
Primary Contact: Mrs. Feng-Yu Lee Correspondent for this Application LumiQuick Diagnostics, Inc. c/o IVDD Regulatory Consultant 27001 La Paz Road Suite 266B Mission Viejo. CA 92691 Tel: (949) 951-3046; Fax: (949) 951-2042 fengvulee@ivddreg.com
Alternate Only:
Mr. Chang Yu (Charles Yu) LumiQuick Diagnostics, Inc 2946 Scott Blvd. Santa Clara, CA 95054 Tel .: (408) 855-0061; Fax: (408) 855-0063 info@lumiquick.com
1
510(k) SUMMARY (Cont.) AS REQUIRED BY SECTION 807.92(C)
Identification / Product Name:
OuickProfile™ Single Drug of Abuse Screen Device Quick Profile™ Multi-Drugs of Abuse Screen Device
Description:
One-step, colloidal gold based chromatographic immunoassay for the rapid, qualitative detection of Amphetamine, Barbiturates, Benzodiazepines, Cocaine, Methadone, Methamphetamine. Opiates, Phencyclidine, and Marijuana in human urine.
Intended Use:
The LumiQuick's QuickProfile™ Single Drugs of Abuse and QuickProfile™ Multi-Drugs of Abuse Screen Devices are rapid chromatographic immunoassays for the qualitative and simultaneous detection of one to nine of the following drugs in a variety of combinations in human urine. Both devices are available in test strip, dip panel, cassette panel and cup formats. The designed cutoff concentrations and direct calibrator for these drugs are as follows:
| AMP | Amphetamine | 1000 ng/ml |
|---|---|---|
| BAR | Secobarbital | 300 ng/ml |
| BZO | Oxazepam | 300 ng/ml |
| COC | Benzoylecgonine | 300 ng/ml |
| MTD | Methadone | 300 ng/ml |
| MAMP | Methamphetamine | 1000 ng/ml |
| OPI | Morphine | 300 ng/ml |
| PCP | Phencyclidine | 25 ng/ml |
| THC | THC 11-nor-Δ"-THC-9-COOH | 50 ng/ml |
These devices are intended for prescription use only. These assays provide only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography / Mass Spectrometry (GC/MS) or Liguid Chromatography / Mass Spectrometry (LC/MS) are the preferred confirmatory method.
Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.
Substantial Equivalence (Predicate Kit):
LumiQuick's QuickProfile™ Single Drugs of Abuse and QuickProfile™ Multi-Drugs of Abuse Screen Devices are substantially equivalent to the predicate device noted below:
Device Name: Innovacon Spectrum II
510(k) numbers for predicate devices are: K061718
2
510(k) SUMMARY (Cont.) AS REQUIRED BY SECTION 807.92(C)
Summary of Device Similarities and Differences
The predicate device and the subject device are identical in functionality and performance. A comparison chart outlining the similarities and differences between the predicate and subject device is shown below:
| Similarities and Differences | ||
|---|---|---|
| Item | QuickProfile | |
| (Subject · Device) | Innovacon | |
| (Predicate Device K061718) | ||
| Indications for Use | Professional Use (non-POC) | Professional Use (POC) |
| Device Format | Test strip, Dip panel, Cassette | |
| panel, and Cup | Test Card: Cup | |
| Device Technology | Immunoassay | |
| Test Time | 5 minutes | |
| Cutoff Levels | Same | |
| Storage Conditions | Transportation and Storage Temperature: 2-30 ℃ | |
| Transportation Storage Humidity: N/A (sealed in pouch) | ||
| Unit of measure | ng/ml | |
| Sample type | Urine | |
| Testing procedure | Same | |
| Result(s) Interpretation | Visual | |
| Sample Application | Same | |
| Control Solution | Non-Applicable | |
| Calibration | N/A |
Statement of No Differences:
For the reasons mentioned above, it is concluded that the Subject devices are substantially equivalent to the predicate device in commercial distribution, with respect to indications for use and technology.
3
510(k) SUMMARY (Cont.) AS REQUIRED BY SECTION 807.92(C)
Technology Characteristics:
The DOA Screen Devices are one-step immunoassays in which chemically labeled drugs (drug-protein conjugates) compete for limited antibody binding sites with drugs that may be present in urine. The single and multi-test devices contain one or more than one test strips (single drug or 2-in-1 drugs per test strip) in the dip panel, cassette panel and cup formats. The drug-protein conjugates are pre-coated on the test band of the membrane and the drug antibody-colloidal gold conjugate pads are placed at one end of the membrane. In the absence of drugs in the urine, the solution of the colored antibodycolloidal gold conjugates move along with the sample solution upward chromatographically by capillary action across the membrane to the immobilized drugprotein conjugate zones on the test band region. The colored antibody-gold conjugates then attach to the drug-protein conjugates to form visible lines as the antibodies complex with the drug conjugates. Therefore, the formation of the visible precipitant in the test band occurs when the test urine is negative for the drug. When drug is present in the urine, the drug/metabolite antigen competes with drug-protein conjugates on the test band region for the limited antibody on the colored drug antibody-colloidal gold conjugate pad. When a sufficient concentration of the drug is present, it will fift the limited antibody binding sites. This will prevent attachment of the colored antibody (drug-protein conjugate)-colloidal gold conjugate to the drug-protein conjugate zone on the test band region. Therefore, absence of the color band on the test region indicates a positive result.
Discussion of Non-clinical Test Performed:
Non-clinical tests were evaluated to establish the performance, functionality, safety and reliability of the OuickProfile™ devices. The performance evaluations include: Sensitivity, Precision - (usability), Stability (Device and Specimen), Reading Time, Specificity and Interference.
These studies evaluations were performed internally by professional personnel in LumiQuick Diagnostics, by qualified lab personnel, with proper calibrated / maintained lab equipments and under properly-controlled environmental conditions according to study requirements. All of the evaluated performances passed and meet the acceptance criteria set in the study protocol.
Discussion of Clinical Tests Performed:
The Accuracy and Comparison Study was performed by comparing the GC/MS confirmed drug concentration on the QuickProfile™ devices and Predicate kit, using unaltered urine specimens, by lab professionals.
Minimum of 87 urine specimens were evaluated per drug, the study results demonstrate 100% accuracy between subject device and GC/MS confirmation level.
4
510(k) SUMMARY (Cont.) AS REQUIRED BY SECTION 807.92(C)
Performance:
The product performance characteristics of LumiQuick's QuickProfile™ Single Drugs of Abuse and QuickProfile™ Multi-Drugs of Abuse Screen Devices were evaluated in the blind- labeled clinical specimen correlation study and in the blind-labeled spiked control studies including sensitivity, precision study, etc. Results of these studies demonstrate substantial equivalence between LumiQuick's QuickProfile™ Single Drugs of Abuse and QuickProfile™ Multi-Drugs of Abuse Screen Devices, GC/MS confirmation methodology, as well as Predicate device.
Conclusion:
Results of Accuracy, Sensitivity, Precificity, Interference studies demonstrate substantial equivalence between LumiQuick's QuickProfile™ Single Drugs of Abuse and QuickProfile™ Multi-Drugs of Abuse Screen Devices and the Predicate device. Results also demonstrate that LumiQuick's QuickProfile™ Single Drugs of Abuse and QuickProfile™ Multi-Drugs of Abuse Screen Devices are safe and effective in detecting Amphetamine, Barbiturates, Benzodiazepines, Cocaine, Methadone, Methamphetamine, Opiates, Phencyclidine, and Marijuana in human urine specimen, for Professional (Non-POC) use.
5
Image /page/5/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo features the department's name arranged in a circular fashion around a symbol. The symbol consists of three stylized lines that curve and overlap, creating a sense of movement and connection.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
October 18, 2013
LumiQuick Diagnostics, Inc. C/O Feng-Yu Lee IVDD Regulatory Consultant 27001 La Paz Rd., Suite 266B MISSION VIEJO CA 92691
Re: K130213
Trade/Device Name: QuickProfile™ Single Drugs of Abuse Screen Device QuickProfile™ Multi-drugs of Abuse Screen Device Regulation Number: 21 CFR 862.3870 Regulation Name: Cannabinoid test system Regulatory Class: II Product Code: LDJ, DIO, LCM, DKZ, JXM, DJG, DJC, DJR, DJS Dated: August 29, 2013 Received: September 06, 2013
Dear Ms. Lee:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. Younmust comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
6
If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers. International and Consumer
Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
http://www.fda.gov/MedicalDevices/ResourcesforIndustry/default.htm
Sincerely yours,
Carol EnBeinson -S for
Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
7
Indications for Use
510(k) Number (if known): K130213
Device Name: QuickProfile Single Drugs of Abuse Screen Device QuickProfile Multi-Drugs of Abuse Screen Device
Indications for Use:
LumiQuick's QuickProfile Single Drugs of Abuse and QuickProfile Multi-Drugs of Abuse Screen Devices are rapid chromatographic immunoassays for the qualitative and simultaneous detection of one to nine of the following drugs in a variety of combinations in human urine. Both devices are available in test strip, dip panel, cassette panel and cup formats. The designed cutoff concentrations and direct calibrator for these drugs are as follows:
| AMP | Amphetamine | 1000 ng/ml |
|---|---|---|
| BAR | Secobarbital | 300 ng/ml |
| BZO | Oxazepam | 300 ng/ml |
| COC | Benzoylecgonine | 300 ng/ml |
| MTD | Methadone | 300 ng/ml |
| MAMP | Methamphetamine | 1000 ng/ml |
| OPI | Morphine | 300 ng/ml |
| PCP | Phencyclidine | 25 ng/ml |
| THC | THC 11-nor-Δ⁹-THC-9-COOH | 50 ng/ml |
Prescription Use X (21 CFR Part 801 Subpart D) And/Or
Over the Counter Use (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)
Denise Johnson-lyles -S
Division Sign-Off Office of In Vitro Diagnostics and Radiological Health
510(k) K130213
8
Indications for Use
510(k) Number (if known): K130213
Device Name: QuickProfile Single Drugs of Abuse Screen Device QuickProfile Multi-Drugs of Abuse Screen Device
Indications for Use:
These devices are intended for prescription use only. These assays provide only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography / Mass Spectrometry (GC/MS) or Liquid Chromatography / Mass Spectrometry (LC/MS) are the preferred confirmatory method.
Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.
Prescription Use X (21 CFR Part 801 Subpart D)
And/Or
Over the Counter Use (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)
Denise Johnson-lyles -S
Division Sign-Off Office of In Vitro Diagnostics and Radiological Health
510(k) = K130213 = ===========================================================================================================================================================